<?xml version="1.0" encoding="UTF-8"?>
<p>A clinical study with a filgrastim biosimilar product, and its reference product was conducted to evaluate biosimilarity between the 2 products in terms of PKs, PDs, and safety. The analyses of primary PK and PD parameters showed sufficient biosimilarity between the 2 products, and the safety profiles were comparable.</p>
